deltatrials
Terminated PHASE1 INTERVENTIONAL 4-arm NCT04023071

FT516 in Subjects With Advanced Hematologic Malignancies

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

Sponsor: Fate Therapeutics

Conditions Acute Myelogenous Leukemia B-cell Lymphoma
Interventions Bendamustine Cyclophosphamide FT516 Fludarabine IL-2 Obinutuzumab Rituximab
Updated 15 times since 2019 Last updated: Oct 25, 2023 Started: Oct 4, 2019 Primary completion: Oct 23, 2023 Completion: Oct 23, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated by the Sponsor.

Other terminated trials from Fate Therapeutics

See all terminations from Fate Therapeutics

Other Acute Myelogenous Leukemia trials with similar outcome

Browse all Acute Myelogenous Leukemia trials

Listed as NCT04023071, this PHASE1 trial focuses on Acute Myelogenous Leukemia and B-cell Lymphoma and remains terminated or withdrawn. Sponsored by Fate Therapeutics, it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Feb 2022 · 10 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Nov 2023 · 5 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Jun 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Sep 2022 — Jun 2023 [monthly]

    Recruiting PHASE1

▶ Show 10 earlier versions

  1. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  2. Feb 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  3. Apr 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  5. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. May 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  7. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE1

  8. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1

  10. Aug 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fate Therapeutics
Data source: Fate Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations